[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:adenosquamous-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":43,"states":44},"Adenosquamous Carcinoma",5,4,[8,16,23,29,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04605913","Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w\u002F Metastatic PAC",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:04.640417Z","2026-05-05T02:43:27.639391Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07163273","Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma",[20],"Phase 2","2026-08-26T02:17:56.243868Z","2026-04-29T02:57:57.072540Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05639972","E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers",[12],"2026-08-26T02:17:33.002248Z","2026-07-05T05:32:16.809101Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT07277413","A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors",[33],"Phase 1","2026-08-26T02:16:01.910993Z","2026-07-05T05:32:16.679197Z",{"nct_id":37,"title":38,"phases":39,"status":40,"updated_at":41,"content_modified":42},"NCT05988918","Multicenter Trial of ESK981 in Patients With Select Solid Tumors",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T02:02:51.511154Z","2026-05-05T02:43:29.366306Z",[],[]]